⭐ Up to one-third of patients with #IBD in remission have IBS-like symptoms. A new Rome Foundation–IOIBD consensus defines this phenotype and outlines diagnostic and treatment strategies: ow.ly/KcFh50ZHkfv
🔬📚 Revisión “state of the art” en enfermedad inflamatoria intestinal (EII)
(BMJ, diciembre 2025)
Un repaso actualizado y práctico sobre los aspectos clave de la EII:
1️⃣ Fisiopatología y nuevas dianas terapéuticas
2️⃣ Manifestaciones extraintestinales
3️⃣ Manejo de la colitis ulcerosa aguda grave
4️⃣ Enfermedad de Crohn postquirúrgica
Imprescindible para estar al día en el abordaje integral de la EII.
bmj.com/content/391/bmj-2025…
It was great to see how well the #IBD group at @MayoClinicFLGIH is doing and also great to see a thriving city-wide gut club! Thanks @ibdgijami for hosting! (And the golf cart tour @JHashashMD)
It was an honor to have colleague and mentor @EdwardLoftus2 visit our beautiful @MayoClinicFLGIH campus for the first time! as #IBD visiting professor and @BGFoundation904 Key Note Speaker for Anniversary Gut Club updating us on advances in #IBD
Hospitalized patients with #IBD from
@AmerGastroAssn
1-IBD Workup
2-Endoscopy: Staging + CMV rule out
3-Progression: IV steroid (for uncontrolled) + Daily CRP
4-Assessment: Medical/Surgical rescue (for unresponsive) or Transition to PO (for responsive)
gastrojournal.org/article/S0…
After years of living with Crohn's disease and trying treatments that didn't work, Amy Marshak felt she was running out of options. The chronic illness affected her career, her energy and the everyday family moments she cherished most. At Mayo Clinic, she found a new treatment approach and renewed hope for the future.
Learn more about her treatment: mayocl.in/4h0zIMm@JHashashMD | @MayoClinicGIHep | @MayoClinicFLGIH
We’re your GI home throughout fellowship and beyond! Unlock more resources, and education to support your GI career by joining AGA for free as a first-year trainee. Apply here: gastro.org/membership/benefi….
📣 #CC360 has ⬆️ its 2025 impact factor to 3🏆
🥳Congrats authors, AEs & @CrohnsColitisFn for advancing high quality #MedEd & #IBD care
💻 Submit your manuscript for an impactful 🌎 reach
📲If interested to be an AE (adult & peds IBD, surgery, GastroPsych, PharmD, GastroRD)
Active Crohn’s disease + cancer treatment = complex decisions.
At #CCC2026, experts debated anti-TNF vs IL-23p19 therapy + what matters most when balancing disease control, safety, and patient priorities: gastroendonews.com/a/oTsBAA/…#IBD#CrohnsDisease
Of course !!! You are an amazing teacher and educator !! Congratulations @JHashashMD thank you for all the work you do to shape the next gen of GI stars !
🚨 New Publication! 🚨
Excited to share our new article in @JCGjournal:
“Comparison of Ustekinumab and Vedolizumab Effectiveness in Perianal Crohn’s Disease”
Our findings suggest a potential effectiveness benefit of UST over VZD in patients with PCD, with lower rates of fistula-related surgery and antibiotic use.
@JHashashMD@FarrayeIBD@OmarMTag@jensemineriomd
👉 Read the article here:
doi.org/10.1097/mcg.00000000…